La catena delle opzioni mostra i dati chiave delle opzioni azionarie di FS KKR Capital a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per FS KKR Capital..

FS KKR Capital (NYSE:FSK) Azioni, Catena delle Opzioni

FS KKR CAPITAL CORP

FS KKR Capital

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

FS KKR Capital Corp

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
&nbsp;
SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in animal models—and is designed to avoid the CNS side effects that halted earlier CB1-targeting drugs
&nbsp;
On July 10, 2025, MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) announced new preclinical results from SKNY-1, an oral drug candidate for obesity and nicotine addiction currently under definitive agreement for acquisition. In a validated behavioral model used to measure Cannabinoid 1 receptor (CB1)-related anxiety-like effects, SKNY-1 demonstrated clear reversal of anxiety-related behavior induced by a CB1 activator, setting it apart from earlier CB1-targeting drugs that were discontinued due to serious central nervous system (CNS) effects.
&nbsp;
The study was conducted using the light-dark preference test in zebrafish—a behavioral model used to assess anxiety-related responses. Zebrafish naturally prefer darker environments, but when anxiety levels are elevated, they avoid light even more strongly. Reduced dark preference (i.e., more time spent in the light) is interpreted as a calming effect.
&nbsp;
Four groups were evaluated:
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Control Group (No Drug): Fish displayed balanced light-dark behavior.</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>CP55,940 Group (CB1 Agonist): At high doses, CP55,940 increased time spent in the dark, indicating anxiety-related behavior. At low doses, it produced a calming effect.</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Rimonabant Group (CB1 Inverse Agonist): Increased anxiety-like behavior was observed at both high and low doses of CP55,940. The response was greater than that of the CP55,940 group alone, consistent with previously documented psychiatric effects.</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>SKNY-1 Groups: In animals co-treated with CP55,940, SKNY-1 reversed the anxiety-inducing effects of high-dose CP55,940 and enhanced the calming effects at low doses. In all treatment conditions, SKNY-1 normalized behavior to control or better-than-control levels.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
SKNY-1 is under investigation for its differentiated pharmacological profile, which includes biased CB1 antagonism (blocking β-arrestin signaling while preserving G-protein signaling), partial CB2 receptor activation, mild MAO-B inhibition, and no inhibition of MAO-A as confirmed through in vitro screening. This profile is intended to avoid the psychiatric side effects historically observed with first-generation CB1 antagonists such as rimonabant.
&nbsp;
MIRA Pharmaceuticals, Inc. is currently preparing for shareholder approval in connection with the proposed acquisition of SKNY Pharmaceuticals, Inc. Pending approval, the Company expects to initiate Investigational New Drug (IND)-enabling studies for SKNY-1.

Biotech

News

General

MIRA

MIRA Pharmaceuticals Announces New Preclinical Results From SKNY-1, An Oral Drug Candidate For Obesity And Nicotine Addiction Currently Under Definitive Agreement For Acquisition; Reports Clear Reversal Of Anxiety-Related Behavior In Animal Model

Barclays analyst Brandon Oglenski maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Overweight and raises the price target from $135 to $145.

Price Target

Analyst Ratings

Barclays Maintains Overweight on XPO, Raises Price Target to $145

Offerings

CIVB

Civista Bancshares Launches Public Offering

Barclays analyst Eddie Kim maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Equal-Weight and raises the price target from $37 to $39.

Barclays Maintains Equal-Weight on Valaris, Raises Price Target to $39

UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) appointed a new head of its Medicaid division, a position that had been <a href="https://www.benzinga.com/news/health-care/25/07/46326465/unitedhealth-slammed-with-another-lawsuit-over-119-billion-stock-plunge">unfilled since May. </a>
The Details: UnitedHealth appointed Mike Cotton on Wednesday as the new CEO of its Medicaid division, as confirmed to <a href="https://www.beckerspayer.com/executive-moves/unitedhealth-group-names-new-medicaid-ceo/">Becker's</a>. 
Bobby Hunter, who leads UnitedHealthcare's Medicare business, will now oversee both the Medicare and Medicaid segments.
Read Next: <a href="https://www.benzinga.com/news/health-care/25/07/46326465/unitedhealth-slammed-with-another-lawsuit-over-119-billion-stock-plunge?utm_source=articleShare">UnitedHealth Slammed With Another Lawsuit Over $119 Billion Stock Plunge</a>
In May, Andrew Witty stepped down as CEO of UnitedHealth Group, with Stephen Hemsley returning to the top leadership role. Since Hemsley's return, the company has made several changes to the executive team at Optum, its health services arm.
According to the company, these leadership adjustments reflect the company's ongoing strategy to build an executive team with broad experience across its various businesses.&nbsp;
Cotton, who joined UnitedHealth Group in 2021, previously served as president and CEO of Select Health at Intermountain.
Why It Matters: At the company's annual shareholder meeting, Hemsley acknowledged UnitedHealth's recent struggles, apologized for its performance and emphasized the need to rethink internal processes.&nbsp;
He assured shareholders that <a href="https://www.benzinga.com/markets/large-cap/25/06/45775858/unitedhealth-board-reelects-directors-hikes-dividend-as-ceo-pledges-review-of-medicare-practices">recent financial results</a> have been factored into the company's 2025 Medicare bids and stressed the importance of adopting a fresh perspective on issues that have drawn widespread criticism.&nbsp;
Under Witty, UnitedHealth expanded its dominance in Medicare Advantage, reportedly achieving profit margins on Medicare enrollees roughly double those of traditional Medicare insurers. This advantage was partly due to federal rules and higher government payments for patients with certain chronic conditions.&nbsp;
However, Medicare policy changes announced in 2023 are now reducing or eliminating many of these extra payments, which is expected to have a major financial impact—affecting nearly 900,000 patients, according to an internal analysis.
Despite these headwinds, UnitedHealth continued to pursue Medicare growth for 2025, even in higher-risk patient groups, while competitors pulled back after profit declines in 2024.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>&nbsp;</li>
</ul>
Image: Shutterstock

Health Care

Management

Movers

Trading Ideas

UnitedHealth Hits Reset: New Head Of Medicaid Appointed As CEO Reshapes Team

FANG

Diamondback Energy Says Q2 Average Unhedged Realized Prices $63.23 Per Barrel Of Oil, $0.88 Per Mcf Of Natural Gas, $18.13 Per Barrel Of NGLS; Q2 Average Realized Hedged Prices Were $62.34/barrel Of Oil $1.45/Mcf Of Natural Gas & $18.13/barrel Of NGLS

Civista Bancshares Signs Agreement To Acquire The Farmers Savings Bank; Agreed To Pay $34.925M In Cash And Issue 1,434,491 Shares

Staking infrastructure provider Chorus One has launched a new decentralized application (dApp) for The Open Network (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TON</a>), aimed at simplifying access to pooled staking on the Telegram-linked blockchain. 
The <a href="https://chorus.one/articles/chorus-one-introduces-ton-pool-dapp">rollout </a>of the TON Pool dApp follows the firm's earlier institutional-focused staking product and marks a shift toward broader retail participation in the ecosystem.
The dApp allows users to delegate TON tokens without facing the native network's high minimum staking thresholds, reportedly as steep as 600,000 TON for direct participation, making staking more accessible to users with smaller holdings. 
The tool also abstracts away operational complexities, such as manual validator selection and pool management.
Chorus One has positioned the dApp as a response to existing bottlenecks within the TON staking ecosystem. 
Among them are caps on the number of nominators per pool, which restrict delegation to just 40 addresses, and regulatory challenges tied to liquid staking tokens (LSTs), which are commonly used by third-party platforms and may fall under scrutiny in jurisdictions governed by regulations like the EU's MiCA.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46351536/you-can-stake-ethereum-solana-on-robinhood-but-is-it-worth-the-25-cut">You Can Stake Ethereum, Solana On Robinhood—But Is It Worth The 25% Cut?</a>
Security has also emerged as a key consideration. 
Chorus One noted that the original smart contracts developed by TON Whales, previously leveraged by the firm, contain vulnerabilities that remain unresolved. 
To address this, the new dApp uses smart contracts audited by the security firm Spearbit.
Since its original launch, the TON Pool has reportedly delivered higher staking yields by optimizing for validator election cycles. 
However, the platform's new interface is likely to bring a wider set of users into an ecosystem that, until now, has remained relatively difficult to access compared to staking on networks like Ethereum or Cosmos.
The move also comes amid growing retail and institutional interest in the TON blockchain, which has seen increased visibility through integrations with Telegram's wallet and mini-app ecosystem.
Read Next: • <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46348745/crypto-users-prioritize-investment-education-over-consumption-nexo-report-finds">Crypto Users Prioritize Investment, Education Over Consumption, Nexo Report Finds</a>

Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$TON

Staking TON Just Got Easier — But What Risks Still Remain In The Ecosystem?

Flotek Industries Announces $200M Mixed Shelf Offering

E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) affirms FY2026 sales outlook from $600.000 million-$618.000 million to $600.000 million-$618.000 million vs $606.707 million estimate.

Guidance

ETWO

E2open Parent Holdings Affirms FY2026 Sales Guidance of $600.000M-$618.000M vs $606.707M Est

E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.04 by 25 percent. This is a 25 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $152.600 million which beat the analyst consensus estimate of $148.920 million by 2.47 percent. This is a 0.93 percent increase over sales of $151.200 million the same period last year.

Earnings

Earnings Beats

E2open Parent Holdings Q1 Adj. EPS $0.05 Beats $0.04 Estimate, Sales $152.600M Beat $148.920M Estimate

Barclays analyst Brandon Oglenski maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Overweight and raises the price target from $260 to $270.

Barclays Maintains Overweight on Union Pacific, Raises Price Target to $270

Bunge Files For Resale Of Up To 65.6M Shares By The Selling Stockholders

Barclays analyst Benjamin Budish maintains Tradeweb Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) with a Overweight and lowers the price target from $159 to $152.

Barclays Maintains Overweight on Tradeweb Markets, Lowers Price Target to $152

Vista Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIST#NYSE">VIST</a>) reported quarterly earnings of $2.16 per share which beat the analyst consensus estimate of $2.15 by 0.65 percent. This is a 55.68 percent increase over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $610.542 million which beat the analyst consensus estimate of $591.600 million by 3.20 percent. This is a 53.90 percent increase over sales of $396.715 million the same period last year.

VIST

Vista Energy Q2 EPS $2.16 Beats $2.15 Estimate, Sales $610.542M Beat $591.600M Estimate

Barclays analyst Benjamin Budish maintains TMX Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/X#TSX">X</a>) with a Equal-Weight and raises the price target from C$56 to C$58.

TSX:X

Barclays Maintains Equal-Weight on TMX Group, Raises Price Target to C$58

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) ("VEON"), a global digital operator, and Cohen Circle Acquisition Corp. I ("Cohen Circle"), a special purpose acquisition company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCIR#NASDAQ">CCIR</a>), today announce the execution of non-redemption agreements ("NRAs") totaling approximately USD 52.3 million with accredited institutional investors, including Helikon and Clearline. These commitments cover approximately 5.05 million CCIR Class A shares, securing the minimum USD 50 million cash condition for the proposed business combination of Kyivstar Group Ltd ("Kyivstar Group") and Cohen Circle (the "Business Combination").
The closing of the Business Combination is expected to occur during the third quarter of 2025 and is subject to the approval of Cohen Circle's shareholders and other customary closing conditions. Upon completion of the Business Combination, Kyivstar Group is expected to be listed on the Nasdaq Stock Market ("Nasdaq") under the ticker symbol "KYIV."

CCIR

VEON

VEON And Cohen Circle Secure $52.3M In Non-Redemption Agreements, Meeting Cash Condition For Kyivstar Merger Ahead Of Nasdaq Listing Under Ticker Symbol 'KYIV'

Derivative Activity
For the second quarter of 2025, Diamondback anticipates a net loss on cash settlements for derivative instruments of $37 million and a net non-cash loss on derivative instruments of $160 million as detailed in the table below (in millions):
Gain (loss) on derivative instruments, net: 
Commodity contracts $ (203) 
Interest rate swaps(1) 
7 
2026 WTI Contingent Liability (1) 
Total $ (197) 
Net cash received (paid) on settlements: 
Commodity contracts $ 23 
Interest rate swaps(1) 
(60) 
Total $ (37)
(1)Includes a $52 million realized loss on the early termination of an aggregate $450 million of the previously outstanding $900 million notional amount of interest rate swaps. Diamondback plans to exclude the partial hedge termination from its second quarter return of capital calculation.

Diamondback Energy  Expects $37M Cash Loss, $160M Non-Cash Loss In Q2

LUCK

Lucky Strike Acquires Real Estate At 58 Locations For $306M

Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) has outperformed the market over the past 20 years by 1.25% on an annualized basis producing an average annual return of 9.73%. Currently, Universal Health Services has a market capitalization of $11.86 billion. 
Buying $1000 In UHS: If an investor had bought $1000 of UHS stock 20 years ago, it would be worth $6,367.41 today based on a price of $184.05 for UHS at the time of writing.
<h3>Universal Health Services's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752178512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

FS KKR Capital

FS KKR Capital (FSK) Opzioni

FS KKR Capital (NYSE:FSK) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO